DefinitionThis section has been translated automatically.
Cytostatic agent. Perorally administered, liquor-continuous alkylane.
IndicationThis section has been translated automatically.
- Approved for the treatment of initially diagnosed glioblastoma multiforme concomitant to radiotherapy and subsequently as monotherapy as well as for recurrent or progressive malignant glioma after standard therapy, e.g. glioblastoma multiforme or anaplastic astrocytoma.
- Malignant melanoma ( off-label use).
You might also be interested in
Pregnancy/nursing periodThis section has been translated automatically.
Contraindicated.
Dosage and method of useThis section has been translated automatically.
Melanoma, malignant ( off-label use): 150-200 mg/m2 KO/day p.o. for 5 days, every 4 weeks
Undesirable effectsThis section has been translated automatically.
- Very common: nausea, vomiting, constipation, anorexia, headache and fatigue, seizures (for brain tumors).
- Common: neutropenia, thrombocytopenia, lymphopenia, leucopenia, herpes simplex infections, candida stomatitis, infectious diseases, anxiety, emotional instability, insomnia.
ContraindicationThis section has been translated automatically.
Hypersensitivity to dacarbazin (DTIC), severe myelosuppression.
PreparationsThis section has been translated automatically.
Temodal
Prof. Dr. med. Peter Altmeyer